Kyverna Therapeutics (NASDAQ:KYTX) Downgraded by Wall Street Zen to Sell

Kyverna Therapeutics (NASDAQ:KYTX) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Several other equities analysts have also weighed in on KYTX. Weiss Ratings restated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Monday. HC Wainwright increased their target price on shares of Kyverna Therapeutics from $10.00 to $20.00 and gave the company a “buy” rating in a research note on Monday, October 27th. Wells Fargo & Company raised their target price on shares of Kyverna Therapeutics from $31.00 to $33.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. Finally, Morgan Stanley set a $33.00 price target on shares of Kyverna Therapeutics in a research report on Monday, December 15th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Kyverna Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $28.67.

Kyverna Therapeutics Stock Performance

Shares of NASDAQ KYTX opened at $8.77 on Friday. Kyverna Therapeutics has a 1 year low of $1.78 and a 1 year high of $13.67. The firm has a market cap of $384.13 million, a P/E ratio of -2.35 and a beta of 3.45. The stock has a fifty day moving average price of $7.81 and a two-hundred day moving average price of $5.58.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its earnings results on Wednesday, November 12th. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($0.97) by $0.12. On average, research analysts predict that Kyverna Therapeutics will post -3.29 earnings per share for the current fiscal year.

Insider Activity

In other Kyverna Therapeutics news, major shareholder Biopartners Opportuni Westlake bought 133,333 shares of the company’s stock in a transaction dated Thursday, December 18th. The shares were bought at an average price of $7.50 per share, for a total transaction of $999,997.50. Following the acquisition, the insider directly owned 869,317 shares of the company’s stock, valued at approximately $6,519,877.50. This trade represents a 18.12% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Beth C. Seidenberg purchased 133,333 shares of Kyverna Therapeutics stock in a transaction dated Thursday, December 18th. The stock was bought at an average cost of $7.50 per share, with a total value of $999,997.50. Following the completion of the transaction, the director directly owned 869,317 shares of the company’s stock, valued at $6,519,877.50. This represents a 18.12% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 22.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Kyverna Therapeutics

A number of institutional investors have recently modified their holdings of KYTX. Vanguard Personalized Indexing Management LLC grew its holdings in shares of Kyverna Therapeutics by 25.2% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 19,122 shares of the company’s stock valued at $59,000 after acquiring an additional 3,847 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new stake in shares of Kyverna Therapeutics during the third quarter worth $28,000. Rhumbline Advisers raised its holdings in shares of Kyverna Therapeutics by 22.0% during the first quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock worth $61,000 after acquiring an additional 5,694 shares in the last quarter. Bank of America Corp DE boosted its position in Kyverna Therapeutics by 41.6% during the fourth quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock valued at $81,000 after purchasing an additional 6,400 shares during the last quarter. Finally, Federated Hermes Inc. grew its stake in Kyverna Therapeutics by 22.2% in the second quarter. Federated Hermes Inc. now owns 44,000 shares of the company’s stock valued at $135,000 after purchasing an additional 8,000 shares in the last quarter. Institutional investors and hedge funds own 18.08% of the company’s stock.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.